Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease

Leukemia

Volumn 21, Issue 4, 2007, Pages 764-771

  Baldwin, B R ^a   Li, L ^a   Tse, K F ^a   Small, S ^a   Collector, M ^a   Whartenby, K A ^a   Sharkis, S J ^a   Racke, F ^b   Huso, D ^a,b   Small, D ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; TRANSCRIPTION FACTOR ETV6; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURST FORMING UNIT E; CHROMOSOME 12Q; CHROMOSOME 13P; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 13; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; COLONY FORMING UNIT S; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 33947388857     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404532     Document Type: Article

References (45)

1. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281.
2. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003; 17: 1738-1752.
3. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
4. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
5. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439.
6. Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: Recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003; 10: 31-39.
7. Drexler HG, Quentmeier H. FLT3: Receptor and ligand. Growth Factors 2004; 22: 71-73.
8. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004; 61: 2932-2938.
9. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-318.
10. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005; 105: 4792-4799.
11. Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 2005; 24: 7882-7892.
12. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288.
13. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115: 2159-2168.
14. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 2005; 115: 919-929.
15. Gotze KS, Ramirez M, Tabor K, Small D, Matthews W, Civin CI. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 1998; 91: 1947-1958.
16. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91: 459-463.
17. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995; 86: 1661-1670.
18. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood 1996; 87: 3563-3570.
19. Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85: 1762-1768.
20. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995; 23: 1121-1129.
21. Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Bennett M, Kumar V. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol 1999; 63: 2648-2656.
22. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells. Proc Natl Acad Sci USA 2001; 98: 14541-14546.
23. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-1152.
24. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y et al. Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110-1119.
25. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000; 14: 1766-1776.
26. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-fike gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
27. Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006; 8: 1414-1421.
28. Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005; 102: 16741-16746.
29. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106: 673-680.
30. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000; 95: 3489-3497.
31. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2.flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147-161.
32. Lanzkron SM, Collector MI, Sharkis SJ. Hematopoietic stem cell tracking in vivo: A comparison of short-term and long-term repopulating cells. Blood 1999; 93: 1916-1921.
33. Levis M, Small D. Novel FLT3 tyrosine kinase inhibitors. Expert Opin Investig Drugs 2003; 12: 1951-1962.
34. Sternberg DW, Licht JD. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): Opportunities and challenges. Curr Opin Hematol 2005; 12: 7-13.
35. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. Transgenic models of lymphoid neoplasia and development of a panhematopoietic vector. Oncogene 1999; 18: 5268-5277.
36. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
37. Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997; 179: 174-184.
38. Parajuli P, Mosley RL, Pisarev V, Chavez J, Ulrich A, Varney M et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001; 29: 1185-1193.
39. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A et al. Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 1997; 159: 2222-2231.
40. Wang A, Braun SE, Sonpavde G, Cornetta K. Antileukemic activity of Flt3 ligand in murine leukemia. Cancer Res 2000; 60: 1895-1900.
41. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 1998; 58: 380-383.
42. Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E et al. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 2000; 86: 827-834.
43. Pisarev VM, Parajuli P, Mosley RL, Sublet J, Kelsey L, Sarin PS et al. Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. Int J Immunopharmacol 2000; 22: 865-876.
44. Smith JR, Thackray AM, Bujdoso R. Reduced herpes simplex virus type 1 latency in Flt-3 ligand-treated mice is associated with enhanced numbers of natural killer and dendritic cells. Immunology 2001; 102: 352-358.
45. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100 (Suppl 1): 11842-11849.